Adherium Ltd. (AU:ADR) has released an update.
Adherium Ltd. is poised for significant growth with plans to onboard over 600 patients by next quarter and a robust sales pipeline involving more than 50 healthcare organizations. The company is expanding into the Pharmacy Benefit Management sector, aiming to launch a program in early 2025 that could reach up to 250,000 patients. These strategic efforts, alongside the search for a new CEO, position Adherium for enhanced revenue generation and market expansion.
For further insights into AU:ADR stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
